JP Morgan Chase
TVRD

JP Morgan Chase’s Tvardi Therapeutics TVRD Stock Holding History

JP Morgan Chase’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,617
Closed -$9.08M – 6666
2021
Q1 		$9.08M Buy
+11,617
New +$7.95M ﹤0.01% 2452
2019
Q3 		– Sell
-2,931
Closed -$2.23M – 6002
2019
Q2 		$2.23M Buy
+2,931
New +$2.06M ﹤0.01% 3307
2017
Q3 		– Sell
-2,500
Closed -$1.39M – 5224
2017
Q2 		$1.39M Buy
+2,500
New +$1.59M ﹤0.01% 3262

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

JP Morgan Chase's TVRD Position: Q1 2026 in Review

JP Morgan Chase increased its Tvardi Therapeutics (TVRD) stake by 3.5% in Q1 2026, buying an estimated $337 and bringing the position to 2,565 shares worth $8.21K. The position accounts for ﹤0.01% of the portfolio, ranked #6788.

JP Morgan Chase first reported a position in TVRD in Q1 2014 and has held it in 49 quarters since. The position peaked at $6.78M in Q1 2014. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • JP Morgan Chase held 2,565 shares of Tvardi Therapeutics worth $8.21K as of Q1 2026.
  • JP Morgan Chase bought 86 Tvardi Therapeutics shares in Q1 2026, an estimated $337.
  • Tvardi Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6788 holding.
  • JP Morgan Chase first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • JP Morgan Chase's Tvardi Therapeutics position peaked at $6.78M in Q1 2014.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.